Immunomodulating antibodies and drugs for the treatment of hematological malignancies

被引：13

作者：

Houot, Roch ^{[2
,3
]}

Kohrt, Holbrook ^{[1
]}

Goldstein, Matthew J. ^{[1
]}

Levy, Ronald ^{[1
]}

机构：

[1] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA

[2] Ctr Hosp Univ Rennes, Serv Hematol Clin, Rennes, France

[3] Ctr Hosp Univ Rennes, INSERM, U917, Rennes, France

来源：

CANCER AND METASTASIS REVIEWS | 2011年 / 30卷 / 01期

关键词：

Immunomodulation; Immunotherapy; Monoclonal antibodies; Cytokine; CpG; Thalidomide; Lenalidomide; Cancer; Hematological malignancies; Lymphoma; Leukemia; Myeloma; NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTI-CD40; MONOCLONAL-ANTIBODY; DEPENDENT CELLULAR CYTOTOXICITY; NATURAL-KILLER-CELL; LENALIDOMIDE PLUS DEXAMETHASONE; RANDOMIZED PHASE-II; REGULATORY T-CELLS; COMBINATION IMMUNOTHERAPY; SINGLE-AGENT;

D O I：

10.1007/s10555-011-9274-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of cancer immunotherapy is to induce immune cells to kill tumor and promote immunological memory that protects against tumor recurrence. Most current immunotherapies, such as monoclonal antibodies (mAb), target the tumor cells directly. Advances in our understanding of the immune system such as the role of costimulatory and co-inhibitory receptors, and the advent of new immunomodulatory agents provide new opportunities to target the immune system and enhance anti-tumor immune responses. These promising agents include immunomodulating mAbs, Toll-like receptor agonists, IMiDs, and cytokines. In this review, we discuss the current results of immunomodulating agents in the treatment of hematological malignancies and propose applications that include targeting of the innate and adaptive immune systems as well as combinations with tumor-specific mAbs.

引用

页码：97 / 109

页数：13

共 120 条

[1] Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].

Advani, Ranjana ;

Forero-Torres, Andres ;

Furman, Richard R. ;

Rosenblatt, Joseph D. ;

Younes, Anas ;

Ren, Hong ;

Harrop, Kate ;

Whiting, Nancy ;

Drachman, Jonathan G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377

[2] Interleukin-21: biology and application to cancer therapy [J].

Andorsky, David J. ;

Timmerman, John M. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (09) :1295-1307

[3] Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia [J].

Andritsos, Leslie A. ;

Johnson, Amy J. ;

Lozanski, Gerard ;

Blum, William ;

Kefauver, Cheryl ;

Awan, Farrukh ;

Smith, Lisa L. ;

Lapalombella, Rosa ;

May, Sarah E. ;

Raymond, Chelsey A. ;

Wang, Da-Sheng ;

Knight, Robert D. ;

Ruppert, Amy S. ;

Lehman, Amy ;

Jarjoura, David ;

Chen, Ching-Shih ;

Byrd, John C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2519-2525

[4] Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma [J].

Ansell, SM ;

Witzig, TE ;

Kurtin, PJ ;

Sloan, JA ;

Jelinek, DF ;

Howell, KG ;

Markovic, SN ;

Habermann, TM ;

Klee, GG ;

Atherton, PJ ;

Erlichman, C .

BLOOD, 2002, 99 (01) :67-74

[5] Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients [J].

Ansell, Stephen M. ;

Geyer, Susan M. ;

Maurer, Matthew J. ;

Kurtin, Paul J. ;

Micallef, Ivana N. M. ;

Stella, Philip ;

Etzell, Paul ;

Novak, Anne J. ;

Erlichman, Charles ;

Witzig, Thomas E. .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6056-6063

[6] Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].

Ansell, Stephen M. ;

Hurvitz, Sara A. ;

Koenig, Patricia A. ;

LaPlant, Betsy R. ;

Kabat, Brian F. ;

Fernando, Donna ;

Habermann, Thomas M. ;

Inwards, David J. ;

Verma, Meena ;

Yamada, Reiko ;

Erlichman, Charles ;

Lowy, Israel ;

Timmerman, John M. .

CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453

[7] INTERLEUKIN-12 - A NEW CLINICAL PLAYER IN CYTOKINE THERAPY [J].

BANKS, RE ;

PATEL, PM ;

SELBY, PJ .

BRITISH JOURNAL OF CANCER, 1995, 71 (04) :655-659

[8] Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

[9] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[10] A phase I dose escalation study of a fully human, antagonist Anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. [J].

Bensinger, William ;

Jagannath, Sundar ;

Becker, Pamela S. ;

Anderson, Kenneth C. ;

Stadtmauer, Edward A. ;

Aukerman, Lea ;

Fox, Judith ;

Girish, Sandhva ;

Bilic, Sanela ;

Guzy, Serge ;

Solinger, Alan ;

Dort, Sherri ;

Wang, Yongyu ;

Hurst, Deborah .

BLOOD, 2006, 108 (11) :1021A-1021A

← 1 2 3 4 5 6 7 8 9 10 →